Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
OMX “GlobeNewswire – EU Press Releases”
COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma.
Read entire article: https://www.globenewswire.com/news-release/2022/05/10/2439615/0/en/Evaxion-Biotech-Announces-Successful-Production-of-Personalized-Cancer-Immunotherapies-in-Phase-1-2a-Clinical-Trial-for-EVX-02.html
